Is treating cardiac hypertrophy salutary or detrimental: The two faces of Janus

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 284, Issue 4 53-4, 2003, Pages

  Morisco, Carmine ^a,b   Sadoshima, Junichi ^a   Trimarco, Bruno ^b   Arora, Rohit ^a   Vatner, Dorothy E ^a   Vatner, Stephen F ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; DOPAMINE BETA MONOOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NORADRENALIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

CAPILLARY DENSITY; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; EDITORIAL; ESSENTIAL HYPERTENSION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE HYPERTROPHY; HEART WORK; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

EID: 0037378337     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00990.2002     Document Type: Editorial

References (52)

1. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, and Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 280: 574-577, 1998.
2. Anderson PG, Bishop SP, and Digerness SB. Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats. Circ Res 64: 1127-1136, 1989.
3. Bishop SP, Powell PC, Hasebe N, Shen YT, Patrick TA, Hittinger L, and Vatner SF. Coronary vascular morphology in pressure-overload left ventricular hypertrophy. J Mol Cell Cardiol 28: 141-154, 1996.
4. Bishopric NH, Andreka P, Slepak T, and Webster KA. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opin Pharmacol 1: 141-150, 2001.
5. Bolognese L, Dellavesa P, Rossi L, Sarasso G, Bongo AS, and Scianaro MC. Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vessel coronary artery disease. Am J Cardiol 73: 1-5, 1994.
6. Breisch EA, Houser SR, Carey RA, Spann JF, and Bove AA. Myocardial blood flow and capillary density in chronic pressure overload of the feline left ventricle. Cardiovasc Res 14: 469-475, 1980.
7. Breisch EA, White FC, and Bloor CM. Myocardial characteristics of pressure overload hypertrophy. A structural and functional study. Lab Invest 51: 333-342, 1984.
8. Brilla CG, Janicki JS, and Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 69: 107-115, 1991.
9. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, and Molkentin JD. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19: 6341-6350, 2000.
10. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, and Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 105: 173-178, 1986.
11. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, and Ross J Jr. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 99: 12333-12338, 2002.
12. Condorelli G, Morisco C, Stassi G, Notte A, Farina F, Sgaramella G, de Rienzo A, Roncarati R, Trimarco B, and Lembo G. Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 99: 3071-3078, 1999.
13. Cooper GT, Kent RL, Uboh CE, Thompson EW, and Marino TA. Hemodynamic versus adrenergic control of cat right ventricular hypertrophy. J Clin Invest 75: 1403-1414, 1985.
14. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, and Rockman HA. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105: 85-92, 2002.
15. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, Wang Z, Kerber RE, and Weiss RM. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 101: 2863-2869, 2000.
16. Hittinger L, Mirsky I, Shen YT, Patrick TA, Bishop SP, and Vatner SF. Hemodynamic mechanisms responsible for reduced subendocardial coronary reserve in dogs with severe left ventricular hypertrophy. Circulation 92: 978-986, 1995.
17. Hoshijima M and Chien KR. Mixed signals in heart failure: cancer rules. J Clin Invest 109: 849-855, 2002.
18. Houghton JL, Smith VE, Strogatz DS, Henches NL, Breisblatt WM, and Carr AA. Effect of African-American race and hypertensive left ventricular hypertrophy on coronary vascular reactivity and endothelial function. Hypertension 29: 706-714, 1997.
19. Jalil JE, Doering CW, Janicki JS, Pick R, Clark WA, Abrahams C, and Weber KT. Structural vs. contractile protein remodeling and myocardial stiffness in hypertrophied rat left ventricle. J Mol Cell Cardiol 20: 1179-1187, 1988.
20. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, and Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 64: 1041-1050, 1989.
21. Koren MJ, Devereux RB, Casale PN, Savage DD, and Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114: 345-352, 1991.
22. Levy D, Garrison RJ, Savage DD, Kannel WB, and Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566, 1990.
23. Levy D, Salomon M, D'Agostino RB, Belanger AJ, and Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90: 1786-1793, 1994.
24. Liao P, Georgakopoulos D, Kovacs A, Zheng M, Lerner D, Pu H, Saffitz J, Chien K, Xiao RP, Kass DA, and Wang Y. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci USA 98: 12283-12288, 2001.
25. Liao Y, Cooper RS, McGee DL, Mensah GA, and Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 273: 1592-1597, 1995.
26. MacLellan WR and Schneider MD. Genetic dissection of cardiac growth control pathways. Annu Rev Physiol 62: 289-319, 2000.
27. Marchetti GV, Merlo L, Noseda V, and Visioli O. Myocardial blood flow in experimental cardiac hypertrophy in dogs. Cardiovasc Res 7: 519-527, 1973.
28. Marcus ML. Coronary Circulation in Health and Disease. New York: McGraw-Hill, 1983.
29. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, and Vatner SF. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 84: 735-740, 1999.
30. Michel JB, Salzmann JL, Ossondo Nlom M, Bruneval P, Barres D, and Camilleri JP. Morphometric analysis of collagen network and plasma perfused capillary bed in the myocardium of rats during evolution of cardiac hypertrophy. Basic Res Cardiol 81: 142-154, 1986.
31. Minamino T, Yujiri T, Terada N, Taffet GE, Michael LH, Johnson GL, and Schneider MD. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc Natl Acad Sci USA 99: 3866-3871, 2002.
32. Molkentin JD and Dorn IG, II. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63: 391-426, 2001.
33. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, and Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 13: 1091-1095, 1995.
34. Murray PA and Vatner SF. Reduction of maximal coronary vasodilator capacity in conscious dogs with severe right ventricular hypertrophy. Circ Res 48: 25-33, 1981.
35. Parfrey PS, Harnett JD, Griffiths SM, Taylor R, Hand J, King A, and Barre PE. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 55: 114-120, 1990.
36. Pfeffer MA, Pfeffer JM, and Frohlich ED. Pumping ability of the hypertrophying left ventricle of the spontaneously hypertensive rat. Circ Res 38: 423-429, 1976.
37. Roberts JT, Wearn JT, and Boten I. Quantitative changes in the capillary muscle relationship in human hearts during normal growth and hypertrophy. Am Heart J 21: 617-633, 1941.
38. Sadoshima J and Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 59: 551-571, 1997.
39. Sadoshima J, Montagne O, Wang Q, Yang G, Warden J, Liu J, Takagi G, Karoor V, Hong C, Johnson GL, Vatner DE, and Vatner SF. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest 110: 271-279, 2002.
40. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, and Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 19: 2537-2548, 2000.
41. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, and Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22: 2799-2809, 2002.
42. Stack RS, Rembert JC, Schirmer B, and Greenfield JC Jr. Relation of left ventricular mass to geometry of the proximal coronary arteries in the dog. Am J Cardiol 51: 1728-1731, 1983.
43. Takagi G, Okumura S, Kawabe J, Hong C, Yang G, Meguro T, Takagi I, AY Gaussin V, Vatner DE, Sadoshima J, Homcy CJ, Ishikawa Y and Vatner SF. Adenylyl cyclase type 5 disruption preserves cardiac function in response to pressure overload (Abstract). Circulation Suppl 106: 11-59, 2002.
44. Thomas SA, Matsumoto AM, and Palmiter RD. Noradrenaline is essential for mouse fetal development. Nature 374: 643-646, 1995.
45. Tomanek RJ. Response of the coronary vasculature to myocardial hypertrophy. J Am Coll Cardiol 15: 528-533, 1990.
46. Tomanek RJ, Wangler RD, and Bauer CA. Prevention of coronary vasodilator reserve decrement in spontaneously hypertensive rats. Hypertension 7: 533-540, 1985.
47. Trimarco B, Lembo G, De Luca N, Volpe M, Ricciardelli B, Condorelli G, Rosiello G, and Condorelli M. Blunted sympathetic response to cardiopulmonary receptor unloading in hypertensive patients with left ventricular hypertrophy. A possible compensatory role of atrial natriuretic factor. Circulation 80: 883-892, 1989.
48. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, and Santucci A. Ambulatory blood pressure an independent predictor of prognosis in essential hypertension. Hypertension 24: 793-801, 1994.
49. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, and Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97: 48-54, 1998.
50. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J and Chien KR. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273: 2161-2168, 1998.
51. Woods JD. Relative ischaemia in the hypertrophied heart. Lancet 1: 696-698, 1961.
52. Yamori Y, Mori C, Nishio T, Ooshima A, Horie R, Ohtaka M, Soeda T, Saito M, Abe K, Nara Y, Nakao Y, and Kihara M. Cardiac hypertrophy in early hypertension. Am J Cardiol 44: 964-969, 1979.